Brii Biosciences Limited BRIBF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

27/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Brii Biosciences Limited (BRIBF) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

27/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — BRIBF

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio7.50

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.30

Book Value / Share$0.00

Revenue / Share$0.03

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$-0.73	$20.2M	$-516.84M	-2559.1%
2020	$-1.71	$82.22M	$-1.21B	-1467.2%
2021	$-9.38	$92.54M	$-4.12B	-4452.3%
2022	$-0.63	$51.63M	$-452.63M	-876.7%
2023	$-0.24	$617K	$-174.83M	-28335.3%
2024	$-0.70	$49.94M	$-508.16M	-1017.6%
2025	$-0.30	$18.12M	$-216.88M	-1196.6%